A discussion unfolds about the challenges of using the Omnipod five in conjunction with different continuous glucose monitors (CGMs). With the current reliance on Libre due to issues with Dexcom, the conversation highlights the hope for future compatibility with the anticipated G7. The cost-effectiveness of Libre is also noted as a temporary solution while awaiting advancements in CGM technology.
